BioWorld

April 28, 2010

View Archived Issues

YM Could Bring in Up to $7.75M in Controlled Equity Financing

Read More

Biotie Goes Partner Hunting After Roche Pulls Out of Mab Project

Read More

Adventrx Plunges on Delay in Cancer Drug Resubmission

Read More

Come See Us at BIO 2010 And Get Your Chicago Hat

Read More

Other News To Note

Read More

Stock Movers

Read More

Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data

Impressive, though early stage, Phase I data already has Pluristem Therapeutics Inc. setting the stage for Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. (BioWorld Today) Read More

AB Science Brings in €27.5M After Scaling Back its IPO

No Abstract Read More

Clinic Roundup

Read More